Project Grant K23HL183890
Award Date 7/15/26
Completion Date 5/31/31
Dollars Obligated $170K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $1,725,948 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) effective July 15, 2026, with completion targeted for June 30, 2028. The award funds real-world effectiveness and value research on glucagon-like peptide-1 receptor agonists (GLP-1RAs) for prevention of cardiovascular disease among individuals with...
- Federal Project Grant Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received an $848,141 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, with a completion date of March 31, 2031. The award funds research to develop and validate cardiac magnetic resonance (CMR) imaging-based diagnostic criteria for coronary microvascular dysfunction (MVD)—a condition affecting up to...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center received a $817,358 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 19, 2025, with an ultimate completion date of May 31, 2029. This grant supports the application of modern statistical and epidemiological methods to predict risk and estimate treatment effectiveness for acute myocardial infarction complicated by cardiogenic...
- Federal Grant Award Summary Award Overview: Beth Israel Deaconess Medical Center (BIDMC) received a $693,964 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2025, with a completion date of June 30, 2030. The grant funds comprehensive proteomics profiling to identify novel protein biomarkers associated with youth-onset type 2 diabetes (YOT2D), a rapidly progressive disease affecting young...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $763,858 Project Grant to Brigham & Women's Hospital on September 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The project, titled "Optimizing Cardiovascular Care and Promoting Excellent Health Outcomes for Adults with Diabetes Across Settings," will develop and validate the PREDICT-DM Global Simulation Model to assess the clinical impact, cost-effectiveness,...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $1,789,824 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2026, with completion targeted for June 30, 2028. The project delivers an integrative computational-experimental research platform to advance cardiovascular disease (CVD) risk assessment by characterizing rare coding variants that influence lipid metabolism....
- Federal Grant Award Summary Brigham and Women's Hospital received an award of $855,585 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of August 20, 2025, and a completion date of July 31, 2028. This Project Grant funds the development and adaptation of an antihypertensive self-titration intervention for routine implementation in U.S. primary care settings. The project addresses the clinical challenge...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $784,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through May 31, 2030. The grant funds a research initiative titled "Beyond BMI: Role of Body Composition, Coronary Microvascular Dysfunction and HFPEF in Characterizing Cardiometabolic Disease Phenotypes." The research employs...
- Federal Project Grant Summary Award Details: The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a $1,628,604 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) effective July 15, 2026, with a completion date of June 30, 2028. The research is being conducted in Boston, Massachusetts. Research Scope: This project investigates the molecular regulation of atherosclerosis, specifically focusing on the role of endothelial cell clearance and CD47...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $1.63 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for research on ADAMTS13 in human health and disease. The award, effective June 15, 2026 through May 31, 2028, supports investigation into thrombotic disorders linked by ADAMTS13 deficiency. The metalloprotease enzyme ADAMTS13 is responsible for cleaving...